
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings has demonstrated a strong turnaround in its business, highlighted by a 11.3% increase in Bone Cement and Surgical sales driven by robust placements of the Rosa system. The company has consistently achieved growth that is either in-line with or surpasses its peers over multiple quarters, supported by healthy orthopedic market conditions and recent mergers and acquisitions. Additionally, the performance of its Knee segment, which grew 5.3% globally, indicates successful product adoption, especially within the Persona OsseoTi offerings, showcasing the potential for further operating leverage from ongoing restructuring initiatives.
Bears say
Zimmer Biomet Holdings (ZBH) faces a negative outlook primarily due to stagnant average selling prices (ASP) expected for FY25 and reduced growth estimates across revenue segments, with projected organic growth at only 3.1% for FY26. The company's knee growth has underperformed compared to its peers, and significant execution challenges have led to adjustments in operating margin forecasts, indicating potential difficulties in maintaining competitive market positioning. Additionally, risks such as market share losses, manufacturing issues, slower commercialization of new products like ROSA, and delayed new product introductions further contribute to a cautious sentiment regarding ZBH's financial performance.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares